NVOPartnership•prnewswire•
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
Sentiment:Positive (70)
Summary
WESTBOROUGH, Mass., Aug. 18, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's approval of Wegovy® (semaglutide) for the...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 18, 2025 by prnewswire